Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

CNS Pharmaceuticals, Inc. CNSP NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
31/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$0.50
-81.8%

CNS Pharmaceuticals, Inc. (CNSP) is a Biotechnology company in the Healthcare sector, currently trading at $2.75. It has a SharesGrow Score of 30/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is CNSP = $1 (-81.8% upside).

Valuation: CNSP trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).

Net income is $16M (loss), growing at -3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $328,571 against $5M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 1.98 (strong liquidity). Debt-to-assets is 3.8%. Total assets: $9M.

Analyst outlook: 4 / 4 analysts rate CNSP as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 64/100 (Pass), Income ?/100 (Fail).

$0.50
▼ 81.82% Downside
Average Price Target
The 12-month price target for CNS Pharmaceuticals, Inc. is $0.50.

CNSP SharesGrow Score Overview

37/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CNSP

✗
VALUE Fail
10/100
CNSP trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25). Analyst consensus target is $1, implying -63.6% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
CNSP: +0%/yr revenue is, -3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet CNSP: Debt-to-Equity (D/E) ratio 0.07 (conservative), Current ratio is 1.98 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
CNSP: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 4 / 4 analysts rate CNSP as buy (100%). Analyst consensus target is $1 (-63.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.057-34.8
Volume106.53K
Avg Volume (30D)32.49K
Market Cap$1.58M
Beta (1Y)0.46
Share Statistics
EPS (TTM)-35.75
Shares Outstanding$443.37K
IPO Date2019-11-08
Employees4
CEORami Levin
Financial Highlights & Ratios
EBITDA$-15.99M
Net Income$-15.85M
Operating Income$-15.99M
Total Cash$7.2M
Total Debt$328.57K
Net Debt$-6.87M
Total Assets$8.62M
Price / Earnings (P/E)-0.1
Analyst Forecast
1Y Price Target$0.50
Target High$0.50
Target Low$0.50
Upside-81.8%
Rating ConsensusBuy
Analysts Covering4
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS18978H5081

Price Chart

Track all markets on TradingView
CNSP
CNS Pharmaceuticals, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
2.06 52WK RANGE 34.80

People Also View

VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 IMMX
IMMX
Immix Biopharma, Inc.
$10.04
+1.93%
 ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
 AVRO
AVRO
AVROBIO, Inc.
$1.40
-1.41%
 ZVSA
ZVSA
ZyVersa Therapeutics, Inc.
$0.19
+0.00%
 ENVB
ENVB
Enveric Biosciences, Inc.
$2.03
+4.10%
 CWBR
CWBR
CohBar, Inc.
$0.41
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message